Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 17 of the 44 sources its claims cite were checked for support.
Abstract
Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and/or invasive candidiasis caused by Candida auris .
Overview
CoChat Summary
TL;DR
In a phase 2, open-label, single-arm trial, fosmanogepix was safe and efficacious in 9 ICU patients with candidemia caused by *Candida auris* in South Africa, with DRC-assessed treatment success at EOST and Day 30 survival both 89% (8/9). No treatment-related adverse events were reported, and manogepix showed low MICs against all baseline *C. auris* isolates.
Key findings
- DRC-assessed treatment success at EOST was 89% (8/9; 95% CI 51.8–99.7), and Day 30 survival was 88.9% (8/9). The single EOST failure was a death on Day 11 considered unrelated to FMGX.
- Mycological outcomes: 6/9 had eradication at EOST, 2 were indeterminate, and 1 had recurrence 2 days after stopping FMGX; sustained treatment success at 2 and 4 weeks after EOST was 66.7% (6/9).
- Safety: all 9 participants had TEAEs (48 events), but 0 were study drug-related; 2 participants had 5 SAEs, all considered unrelated to treatment. Two deaths occurred, both assessed as unrelated to FMGX.
- In vitro activity: manogepix MIC range was 0.008–0.015 μg/mL by CLSI and 0.004–0.03 μg/mL by EUCAST, with the lowest MICs among antifungals tested. Median total-drug plasma AUC was 93 mg·h/L, and median AUC:MIC ratio was 7147.
Methods
- Multicenter, open-label, non-comparative, single-arm Phase 2 study (NCT04148287) planned at 4 South Africa sites and 1 Panama site; 9 adults with *C. auris* candidemia and limited treatment options were enrolled at 2 South Africa sites between 10 Dec 2019 and 23 Oct 2020.
- Treatment: FMGX 1000 mg IV twice daily on Day 1, then 600 mg IV once daily; oral switch to 800 mg once daily was permitted from Day 4, up to 42 days. All participants received IV FMGX only.
- Primary endpoint: DRC-assessed treatment success at EOST, defined as survival plus clearance of *C. auris* without additional antifungals. Secondary endpoints included Day 30 survival, time to first negative blood culture, mycological outcomes, safety, and in vitro susceptibility.
Limitations
- The authors state the sample size was small because the study was terminated early due to the COVID-19 pandemic’s ICU burden; all active sites were in South Africa, isolates were likely Clade III, and results may not generalize to all clades.
- The authors note participants had candidemia only, with no deep-seated *C. auris* infections, and PK sampling was sparse, precluding model-based compartmental analysis.
- Evident from the text: the single-arm, open-label, non-comparative design with N=9 and wide confidence intervals limits causal inference; Table 5 also lists 1 TEAE leading to discontinuation of study drug, while the abstract/results state no study drug discontinuations were reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
10 Valid · 3 Not valid · 17 Not checked · 54 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“This is consistent with previous in vitro studies showing MGX to be the most potent antifungal tested against C. auris isolates (21, 22).”
§ Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial > DISCUSSION
What the sources say
- Supportedcites [21] Zhu Y, Kilburn S, Kapoor M, Chaturvedi S, Shaw KJ, Chaturvedi V. 2020. In vitro activity of manogepix against multidrug-resistant and panresistant Candida auris from the New York outbreak. Antimicrob Agents Chemother 64: e01124-20. doi: 10.1128/AAC.01124-20. 32839219 PMC7577132 source
The DISCUSSION of Zhu et al. (2020) states outright that 'MGX was the most active antifungal agent tested against the 200 C. auris isolates in the present study', including panresistant isolates. The RESULTS (Tables 1-3) and ABSTRACT quantify it: MGX MIC50/MIC90 0.03 mg/liter (range 0.004-0.06), 8- to 32-fold more active than the echinocandins, 16- to 64-fold more active than the azoles, 64-fold more active than amphotericin B and >1,000-fold more active than 5FC. This is exactly the in vitro potency claim the citing sentence attributes to it. (LLM, conf=0.92)
- Supportedcites [22] Arendrup MC, Chowdhary A, Jørgensen KM, Meletiadis J. 2020. Manogepix (APX001A) in vitro activity against Candida auris: head-to-head comparison of EUCAST and CLSI MICs. Antimicrob Agents Chemother 64: e00656-20. doi: 10.1128/AAC.00656-20. 32660998 PMC7508601 source
The Abstract of Arendrup et al. (2020) concludes that 'manogepix was the most potent agent against C. auris in this in vitro study,' and the Discussion (p. 'DISCUSSION') states 'the in vitro activity of manogepix was highly potent on a mg/liter basis.' Table 1 (Manogepix MICs section) documents this head-to-head ranking across nine compounds: MGX MIC50 0.008 (CLSI) / 0.016 (EUCAST) mg/liter, below posaconazole (0.016/0.03), anidulafungin, micafungin, isavuconazole, itraconazole, voriconazole, amphotericin B and fluconazole against the 122 C. auris isolates. The cited paper therefore is one of the previous in vitro studies showing manogepix to be the most potent antifungal tested against C. auris isolates. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Broad-spectrum antifungal activity has been observed against pathogenic yeasts and molds, including activity against resistant strains (16–18).”
§ Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial > INTRODUCTION
What the sources say
- Supportedcites [16] Hager CL, Larkin EL, Long L, Abidi FZ, Shaw KJ, Ghannoum MA. 2018. In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob Agents Chemother 62: e02319-17. doi: 10.1128/AAC.02319-17. 29311065 PMC5826120 source
The Introduction states verbatim the substance of the claim: 'APX001A has broad in vitro activity against major fungal pathogens, including Candida, Cryptococcus, Aspergillus, Scedosporium, Fusarium, and members of the Mucorales order (13–17). It maintains its activity against azole-resistant and echinocandin-resistant strains' — yeasts and molds plus activity against resistant strains. The paper's own data reinforce the resistant-strain component: Results ('Antifungal susceptibility profile') report APX001A MIC50 0.004 / MIC90 0.031 μg/ml against all 16 C. auris isolates, many with elevated fluconazole and amphotericin B MICs, and the Abstract/Discussion frame C. auris as multidrug-resistant. No qualifier in the claim (pathogenic yeasts and molds, resistant strains) exceeds what our copy asserts. (LLM, conf=0.86)
- Supportedcites [17] Shaw KJ, Schell WA, Covel J, Duboc G, Giamberardino C, Kapoor M, Moloney M, Soltow QA, Tenor JL, Toffaletti DL, Trzoss M, Webb P, Perfect JR. 2018. In vitro and in vivo evaluation of APX001A/APX001 and other Gwt1 inhibitors against cryptococcus. Antimicrob Agents Chemother 62: e00523-18. doi: 10.1128/AAC.00523-18. 29891599 PMC6105804 source
The Introduction of Shaw et al. (2018) states in its own voice that 'APX001A has broad in vitro activity against major fungal pathogens, including Candida, Cryptococcus, Aspergillus, Scedosporium, Fusarium, and members of the Mucorales order' — i.e., pathogenic yeasts and molds — and immediately adds that 'it is active against azole-resistant and echinocandin-resistant strains,' covering the resistant-strain element of the claim. The Discussion reinforces this by describing APX001 as a 'first-in-class, i.v. and orally available broad-spectrum antifungal agent,' and the Results (Table 1) report MIC/MEC values of 0.004–0.25 μg/ml against C. neoformans, C. gattii, C. albicans and A. fumigatus. The claim is a broader paraphrase of the same content (it does not name the genera or specify azole/echinocandin resistance), which the source supports at equal or greater specificity. (LLM, conf=0.86)
- Supportedcites [18] Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR. 2018. In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated candidiasis mouse model. Antimicrob Agents Chemother 62: e02542-17. doi: 10.1128/AAC.02542-17. 29378706 PMC5913987 source
The Introduction of our copy states the claim almost verbatim: APX001A/APX001 'exhibit broad-spectrum activity against pathogenic yeasts (e.g., Candida spp.) and molds (e.g., Aspergillus spp.), including multidrug-resistant strains'. The Discussion reinforces it, reporting that the authors' own in vivo studies showed APX001 active against C. albicans, C. glabrata and C. auris 'including against isolates resistant to fluconazole and micafungin', and that APX001A retained potency against fluconazole- and caspofungin-resistant Candida strains. The mold/multidrug-resistant-mold portion of the sentence is carried in our copy with citations to prior E1210 in vitro work (refs 13-16), but the paper itself adopts it as a stated property of the agent, which suffices for a broad background claim cited alongside other references. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Surveillance studies have demonstrated that MGX was the most mycologically active agent against over 400 diverse C. auris isolates, including strains which were multi-drug resistant (19, 20).”
§ Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial > INTRODUCTION
What the sources say
- Partly supportedcites [19] Berkow EL, Lockhart SR. 2018. Activity of novel antifungal compound APX001A against a large collection of Candida auris. J Antimicrob Chemother 73: 3060– 3062. doi: 10.1093/jac/dky302. 30085167 sourceExperimental — accuracy not yet measured
The Methods describe 100 geographically diverse C. auris isolates, including two resistant to all three antifungal drug classes. The Discussion reports potent APX001A activity even against those resistant isolates. This paper does not establish activity against over 400 isolates or identify APX001A as the most active agent. (LLM, conf=0.90)
- Partly supportedcites [20] Maphanga TG, Naicker SD, Kwenda S, Muñoz JF, Schalkwyk EV, Wadula J, Nana T, Ismail A, Coetzee J, Govind C, Mtshali PS, Mpembe RS, Govender NP, for GERMS-S. 2021. In vitro antifungal resistance of Candida auris isolates from bloodstream infections, South Africa. Antimicrob Agents Chemother 65: e0051721. doi: 10.1128/AAC.00517-21. 34228535 PMC8370198 sourceExperimental — accuracy not yet measured
The Results (page unavailable) report surveillance testing of 400 C. auris isolates, including multidrug-resistant isolates. They do not report testing MGX or comparing its activity with other agents, and the sample was 400 isolates, not over 400. (LLM, conf=0.86)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“When in vitro activity of MGX was evaluated against eight comparator agents against 122 wild type and non-wild type C. auris isolates, similar findings were reported, with MGX having the most potent antifungal activity against all C. auris strains (22).”
§ Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial > INTRODUCTION
What the sources say
- Supportedcites [22] Arendrup MC, Chowdhary A, Jørgensen KM, Meletiadis J. 2020. Manogepix (APX001A) in vitro activity against Candida auris: head-to-head comparison of EUCAST and CLSI MICs. Antimicrob Agents Chemother 64: e00656-20. doi: 10.1128/AAC.00656-20. 32660998 PMC7508601 source
The paper says it tested manogepix and eight comparators against 122 C. auris isolates. Its Abstract describes a population suggesting a mix of wild-type and non-wild-type isolates and concludes that manogepix was the most potent agent in this in vitro study. No page numbers are available in our copy. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“C. auris is well known for its multi-drug resistant characteristics, with most isolates resistant to fluconazole, an important first-line antifungal agent (3, 6, 10, 11).”
§ Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial > INTRODUCTION
What the sources say
- Partly supportedcites [3] Magobo RE, Corcoran C, Seetharam S, Govender NP. 2014. Candida auris-associated candidemia, South Africa. Emerg Infect Dis 20: 1250– 1251. doi: 10.3201/eid2007.131765. 24963796 PMC4073876 sourceExperimental — accuracy not yet measured
The main text reports high fluconazole MICs for all four C. auris isolates studied, and the susceptibility table lists values of 64 or >256 μg/mL. These findings support resistance in the South African isolates examined, but the study of four isolates does not establish that most C. auris isolates generally are resistant. (LLM, conf=0.84)
- Not checked yetcites [6] Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J, Palmore TN, Zelzany A, Adams EH, Quinn M, Chaturvedi S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J, Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, Chiller TM. 2017. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013-August 2016. Am J Transplant 17: 296– 299. doi: 10.1111/ajt.14121. 280 source
- Supportedcites [10] Chowdhary A, Kumar VA, Sharma C, Prakash A, Agarwal K, Babu R, Dinesh KR, Karim S, Singh SK, Hagen F, Meis JF. 2014. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 33: 919– 926. doi: 10.1007/s10096-013-2027-1. 24357342 source
The Antifungal susceptibility testing section reports that all 15 C. auris isolates tested were resistant to fluconazole. The Introduction also describes fluconazole resistance as a reported characteristic of C. auris. The study's direct measurements are limited to its isolates from south India. (LLM, conf=0.91)
- Supportedcites [11] Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-James D, Fisher MC. 2016. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 5: 35. doi: 10.1186/s13756-016-0132-5. 27777756 PMC5069812 source
The Results section (Characteristics and typing of outbreak strains) reports that all isolates in this hospital outbreak had high-level fluconazole resistance. The Discussion also describes high-level resistance to fluconazole as characteristic of C. auris, supporting the citing sentence’s broader phrasing. (LLM, conf=0.90)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
40 more claims · 1 with their cited sources checked
Create a free account to see all 84 claims and to verify the 27 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 21
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Results from a Phase 2 clinical trial for patients with candidemia from C. auris demonstrated safety and efficacy of fosmanogepix.161”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [161]
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Self-citationLockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 1×
“auris infections resulting in death (8).”
Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
First hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768 · cited 1×
“resistant to fluconazole, an important first-line antifungal agent (3, 6, 10, 11).”
BackgroundChow, N. A., Muñoz, J. F., Gade, L., Berkow, E., Li, X., Welsh, R. M., Forsberg, K., Lockhart, S. R., Adam, R., Alanio, A., et al. (2020) · doi:10.1101/2020.01.06.896548 · Cited by 463
Candida auris: an Emerging Fungal Pathogen
Spivak, E. S., & Hanson, K. E. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01588-17 · Cited by 393
Multidrug-resistant endemic clonal strain of Candida auris in India
Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K. R., Karim, S., Singh, S. K., Hagen, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2027-1 · Cited by 373 · cited 1×
“resistant to fluconazole, an important first-line antifungal agent (3, 6, 10, 11).”
BackgroundEmerging Fungal Infections: New Patients, New Patterns, and New Pathogens
Friedman, D. Z. P., & Schwartz, I. S. (2019) · Journal of Fungi · doi:10.3390/jof5030067 · Cited by 357
Multidrug-Resistant Candida haemulonii and C. auris , Tel Aviv, Israel
Ben-Ami, R., Berman, J., Novikov, A., Bash, E., Shachor-Meyouhas, Y., Zakin, S., Maor, Y., Tarabia, J., Schechner, V., Adler, A., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161486 · Cited by 297
Candida auris–Associated Candidemia, South Africa
Magobo, R. E., Corcoran, C., Seetharam, S., & Govender, N. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.131765 · Cited by 259
Vallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14121 · Cited by 247
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00238-18 · Cited by 247
Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200
Watanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00731-11 · Cited by 169
Confirmation of fifth Candida auris clade by whole genome sequencing
Spruijtenburg, B., Badali, H., Abastabar, M., Mirhendi, H., Khodavaisy, S., Sharifisooraki, J., Taghizadeh Armaki, M., de Groot, T., & Meis, J. F. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125349 · Cited by 164 · cited 1×
“Currently, 5 clades have been identified, based on genetic sequence and geographical origin (2, 7).”
BackgroundBurden of Candidemia in the United States, 2017
Tsay, S. V., Mu, Y., Williams, S., Epson, E., Nadle, J., Bamberg, W. M., Barter, D. M., Johnston, H. L., Farley, M. M., Harb, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa193 · Cited by 163
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
McLellan, C. A., Whitesell, L., King, O. D., Lancaster, A. K., Mazitschek, R., & Lindquist, S. (2012) · ACS Chemical Biology · doi:10.1021/cb300235m · Cited by 115
Lyman, M., Forsberg, K., Reuben, J., Dang, T., Free, R., Seagle, E. E., Sexton, D. J., Soda, E., Jones, H., Hawkins, D., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7029a2 · Cited by 104
Candida auris outbreak: Mortality, interventions and cost of sustaining control
Taori, S. K., Khonyongwa, K., Hayden, I., Athukorala, G. D. A., Letters, A., Fife, A., Desai, N., & Borman, A. M. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.09.007 · Cited by 86
Candida auris Invasive Infections during a COVID-19 Case Surge
Hanson, B. M., Dinh, A. Q., Tran, T. T., Arenas, S., Pronty, D., Gershengorn, H. B., Ferreira, T., Arias, C. A., & Shukla, B. S. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01146-21 · Cited by 81 · cited 1×
“auris infections have also increased during the COVID-19 pandemic, straining health care capacity, and increasing the risk of multidrug resistant nosocomial infections (34).”
BackgroundIn Vitro Antifungal Resistance of Candida auris Isolates from Bloodstream Infections, South Africa
Maphanga, T. G., Naicker, S. D., Kwenda, S., Muñoz, J. F., van Schalkwyk, E., Wadula, J., Nana, T., Ismail, A., Coetzee, J., Govind, C., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00517-21 · Cited by 78
Wiederhold, N. P., Najvar, L. K., Shaw, K. J., Jaramillo, R., Patterson, H., Olivo, M., Catano, G., & Patterson, T. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01120-19 · Cited by 71
Zhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68
Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad256 · Cited by 65
Self-citationActivity of novel antifungal compound APX001A against a large collection of Candida auris
Berkow, E. L., & Lockhart, S. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky302 · Cited by 57
Zhu, Y., Kilburn, S., Kapoor, M., Chaturvedi, S., Shaw, K. J., & Chaturvedi, V. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01124-20 · Cited by 50 · cited 1×
“, azoles, polyenes, and echinocandins) (21).”
Arendrup, M. C., Chowdhary, A., Jørgensen, K. M., & Meletiadis, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00656-20 · Cited by 49 · cited 1×
“auris isolates (22), the agreement between CLSI and EUCAST MICs for MGX were high (equal to or within 1 dilution for 8/9 isolates) while anidulafungin MICs were different (2 to 16-fold) between CLSI and EUCAST methods for all 9 isolates.”
ResultGovender, N. P., Avenant, T., Brink, A. J., Chibabhai, V., Cleghorn, J., du Toit, B., Govind, C., Lewis, E., Lowman, W., Mahlangu, H., et al. (2019) · Southern African Journal of Infectious Diseases · doi:10.4102/sajid.v34i1.163 · Cited by 46
Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R., Van Marle, S. J., Van Hoogdalem, E.-J., Wedel, P., & Kramer, W. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1370 · Cited by 40
Self-citationAl-Obaid, I., Asadzadeh, M., Ahmad, S., Alobaid, K., Alfouzan, W., Bafna, R., Emara, M., & Joseph, L. (2022) · Journal of Fungi · doi:10.3390/jof8030267 · Cited by 39 · cited 1×
“Almost all identified strains are resistant to at least 2 classes of antifungals (azoles and polyenes), with some strains demonstrating multi-drug resistance (azole-polyene-candin) (29).”
BackgroundFour genomic clades of Candida auris identified in Canada, 2012–2019
De Luca, D. G., Alexander, D. C., Dingle, T. C., Dufresne, P. J., Hoang, L. M., Kus, J. V., Schwartz, I. S., Mulvey, M. R., & Bharat, A. (2022) · Medical Mycology · doi:10.1093/mmy/myab079 · Cited by 22
Mansbach, R., Shaw, K. J., Hodges, M. R., Coleman, S., & Fitzsimmons, M. E. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1209 · Cited by 21
Self-citationPappas, P., Kullberg, B. J., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., McCarty, T. P., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa439.457 · Cited by 17
Self-citation
Research works printed but not linked: 1
- 10.1128/aac.01120-1 · doi:10.1128/aac.01120-1
Cited by
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 184
Advancements and challenges in antifungal therapeutic development
Puumala, E., Fallah, S., Robbins, N., & Cowen, L. E. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00142-23 · Cited by 140
Yuan, Y., Li, P., Li, J., Zhao, Q., Chang, Y., & He, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01759-7 · Cited by 130
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Self-citationGiannella, M., Lanternier, F., Dellière, S., Groll, A. H., Mueller, N. J., Alastruey‐Izquierdo, A., & Slavin, M. A. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.08.006 · Cited by 106
Metadata
- Authors
- Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R.
- Affiliations
- Medical College of Georgia, Augusta University, Augusta, Georgia, USA
- University of Alabama at Birmingham (US)
- University of the Witwatersrand (ZA)
- Steve Biko Hospital (ZA)
- Amplyx Pharmaceuticals (United States) (US)
- Pfizer (United States) (US)
- Corresponding author
- Tawadrous, Margaret
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2023-05-17
- Volume
- 67
- Issue
- 5
- Pages
- e0141922-e0141922
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC10190264
- OpenAlex
- W4362658239
- Cited by
- 92
- References
- 35
- Citations by year
- 2026: 29 · 2025: 22 · 2024: 33 · 2023: 7
- FWCI
- 18.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UpSpace Institutional Repository (University of Pretoria) (submittedVersion, cc-by)
- Funders
- Amplyx
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- fosmanogepix, Candida auris, candidemia, invasive candidiasis, antifungal agents, antifungal resistance, treatment efficacy, drug safety
- MeSH terms
- Candida auris, Antifungal Agents, Candidiasis, Female, Humans, Male, Microbial Sensitivity Tests, Treatment Outcome, Isocyanates, Candidiasis, Invasive, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.